About Pharma Nord
In 1981, Danish entrepreneurs Eli Wallin and Sven Moesgaard set out to address the nutritional gaps in modern diets. Their initial focus was importing a selenium supplement, but they soon developed Bio-Selenium+Zinc, a formulation that remains a cornerstone of Pharma Nord’s product range today.
From the start, Pharma Nord prioritised scientific integrity, focusing on supplements with high bioavailability, ensuring nutrients are effectively absorbed and backed by rigorous research. This approach led to a major milestone in 1990 when Pharma Nord became the first company to introduce coenzyme Q10 to the European market. Bio-Quinone Q10 has since become one of the world’s leading Q10 supplements, widely recognised for its role in cellular energy production and cardiovascular health.
The Science Behind Coenzyme Q10
Coenzyme Q10, also known as ubiquinone, is found in every cell of the body, particularly in high-energy tissues like the heart. It plays a critical role in ATP production which is the molecule that fuels cellular processes. However, in its raw form, Q10 is lipid-soluble and difficult for the body to absorb.
Pharma Nord tackled this issue with a patented manufacturing technique that dissolves Q10 crystals at body temperature using a specialised blend of vegetable oils. This method significantly enhances bioavailability, a factor confirmed in clinical studies. Many competitor products fail to achieve the same absorption levels, leading to inconsistent results in clinical trials.
Science and Quality at the Core
In an industry where trust is essential, Pharma Nord sets itself apart by adhering to pharmaceutical-grade production standards. While dietary supplement regulations vary globally, the company ensures its entire range meets medicinal criteria. Every product undergoes stringent quality control and is manufactured using carefully sourced natural ingredients, guaranteeing scientifically documented efficacy.
Beyond manufacturing, Pharma Nord actively collaborates with researchers, healthcare professionals, and institutions to advance nutritional science. By committing to evidence-based nutrition, the company ensures its supplements provide measurable health benefits.
A Global Vision Backed by Research
What began as a single product has grown into an international enterprise. Pharma Nord quickly expanded into Sweden, England, and Finland, and today, its presence spans the globe. As the demand for scientifically validated supplements rises, Pharma Nord remains committed to maintaining the highest standards of efficacy, transparency, and research-driven innovation.
University of Bristol Launches New Research Project on Q10’s Role in Heart Failure
The UK Government’s Department of Health and Social Care has awarded a £2 million grant through the National Institute for Health and Care Research to further investigate the use of Q10 in people with heart failure.
Lead cardiologist Dr. Angus Nightingale highlights that Q10 is believed to improve survival rates and reduce hospital admissions in patients with chronic heart failure. The new study will explore whether Q10 can also alleviate symptoms and enhance patients’ quality of life. Additionally, researchers will assess whether these potential benefits could help reduce the socio-economic burden of heart failure.
Pharma Nord has been chosen to supply the Q10 preparations for this newly launched study in England, just as it previously provided Q10 for the KiSel-10 and Q-Symbio studies conducted at Rigshospitalet in Copenhagen
Research:
Singh RB, et al. Effects on absorption and oxidative stress of different oral Coenzyme Q10 dosages and intake strategy in healthy men. Biofactors 2005;25(1-4):219-24.
Weis M, et al. Bioavailability of Four Oral Coenzyme Q10 Formulations in Healthy Volunteers. Mol Aspect Med 199415s,273-80.
López-Lluch G, et al. Bioavailability of coenzyme Q10 supplements depends on carrier lipids and solubilization. Nutrition 2019;57:133-40.
Alehagen U, Aaseth J, Johansson P. Reduced Cardiovascular Mortality 10 Years after Supplementation with Selenium and Coenzyme Q10 for Four Years: Follow-Up Results of a Prospective Randomized Double-Blind Placebo-Controlled Trial in Elderly Citizens. PLoS One. 2015;10(12):e0141641.
Mortensen SA, Rosenfeldt F, Kumar A, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2014;2(6):641-649.
Learn more about our products on https://www.pharmanord.co.uk/all-products
